{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T21:11:27Z","timestamp":1787605887601,"version":"build-2736575974"},"reference-count":39,"publisher":"American Medical Association (AMA)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Ophthalmol"],"published-print":{"date-parts":[[2021,4,1]]},"DOI":"10.1001\/jamaophthalmol.2020.6591","type":"journal-article","created":{"date-parts":[[2021,2,8]],"date-time":"2021-02-08T12:35:34Z","timestamp":1612787734000},"page":"389","source":"Crossref","is-referenced-by-count":15,"title":["Opportunities to Reduce Potential Bias in Ophthalmic Cost-Utility Analysis"],"prefix":"10.1001","volume":"139","author":[{"given":"Gary C.","family":"Brown","sequence":"first","affiliation":[{"name":"Center for Value-Based Medicine, Hilton Head, South Carolina"},{"name":"Wills Eye Hospital, Thomas Jefferson Medical University, Philadelphia, Pennsylvania"},{"name":"Department of Ophthalmology, Emory University School of Medicine, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa M.","family":"Brown","sequence":"additional","affiliation":[{"name":"Center for Value-Based Medicine, Hilton Head, South Carolina"},{"name":"Wills Eye Hospital, Thomas Jefferson Medical University, Philadelphia, Pennsylvania"},{"name":"Department of Ophthalmology, Emory University School of Medicine, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imtiaz","family":"Chaudhry","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Aria-Jefferson Health, Philadelphia, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua D.","family":"Stein","sequence":"additional","affiliation":[{"name":"Glaucoma Service, University of Michigan Kellogg Eye Center, Ann Arbor"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"10","key":"eoi200114r1","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1001\/jama.2016.12195","article-title":"Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: Second Panel on Cost-Effectiveness in Health and Medicine.","volume":"316","author":"Sanders","year":"2016","journal-title":"JAMA"},{"issue":"1","key":"eoi200114r3","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1136\/bjo.87.1.8","article-title":"Quality of life with macular degeneration: perceptions of patients, clinicians, and community members.","volume":"87","author":"Stein","year":"2003","journal-title":"Br J Ophthalmol"},{"issue":"1","key":"eoi200114r4","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1136\/bjo.86.1.8","article-title":"Quality of life and systemic comorbidities in patients with ophthalmic disease.","volume":"86","author":"Brown","year":"2002","journal-title":"Br J Ophthalmol"},{"issue":"6","key":"eoi200114r5","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1136\/bjo.2007.127407","article-title":"The effect of comorbidities upon ocular and systemic health-related quality of life.","volume":"92","author":"Real","year":"2008","journal-title":"Br J Ophthalmol"},{"key":"eoi200114r6","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/1478-7954-9-10","article-title":"The effect of comorbidity on health-related quality of life for injury patients in the first year following injury: comparison of three comorbidity adjustment approaches.","volume":"9","author":"Haagsma","year":"2011","journal-title":"Popul Health Metr"},{"issue":"9","key":"eoi200114r7","doi-asserted-by":"publisher","first-page":"2475","DOI":"10.1007\/s11136-020-02514-5","article-title":"Health gap for multimorbidity: comparison of models combining uniconditional health gap.","volume":"29","author":"Park","year":"2020","journal-title":"Qual Life Res"},{"issue":"3","key":"eoi200114r8","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.survophthal.2018.11.001","article-title":"Health care stakeholder perceptions of vision loss.","volume":"64","author":"Brown","year":"2019","journal-title":"Surv Ophthalmol"},{"issue":"3","key":"eoi200114r9","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/S0008-4182(00)80005-8","article-title":"Difference between ophthalmologists\u2019 and patients\u2019 perceptions of quality of life associated with age-related macular degeneration.","volume":"35","author":"Brown","year":"2000","journal-title":"Can J Ophthalmol"},{"issue":"3","key":"eoi200114r10","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.jcjo.2015.02.004","article-title":"Medical student and patient perceptions of quality of life associated with vision loss.","volume":"50","author":"Chaudry","year":"2015","journal-title":"Can J Ophthalmol"},{"issue":"3","key":"eoi200114r11","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.jval.2019.01.004","article-title":"Identification, review, and use of health state utilities in cost-effectiveness models: an ISPOR Good Practices for Outcomes Research Task Force Report.","volume":"22","author":"Brazier","year":"2019","journal-title":"Value Health"},{"key":"eoi200114r13","first-page":"473","article-title":"Vision and quality-of-life.","volume":"97","author":"Brown","year":"1999","journal-title":"Trans Am Ophthalmol Soc"},{"issue":"3","key":"eoi200114r14","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1136\/bjo.85.3.327","article-title":"Utility values associated with blindness in an adult population.","volume":"85","author":"Brown","year":"2001","journal-title":"Br J Ophthalmol"},{"issue":"4","key":"eoi200114r15","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/S0008-4182(01)80041-7","article-title":"Reliability of the time trade-off technique of utility assessment in patients with retinal disease.","volume":"36","author":"Hollands","year":"2001","journal-title":"Can J Ophthalmol"},{"issue":"5","key":"eoi200114r16","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1136\/bjo.86.5.493","article-title":"Validity of the time trade-off and standard gamble methods of utility assessment in retinal patients.","volume":"86","author":"Sharma","year":"2002","journal-title":"Br J Ophthalmol"},{"issue":"11","key":"eoi200114r17","doi-asserted-by":"publisher","first-page":"4016","DOI":"10.1167\/iovs.05-0072","article-title":"The impact of age-related macular degeneration on health status utility values.","volume":"46","author":"Espallargues","year":"2005","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"11","key":"eoi200114r18","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.3111\/13696998.2013.839946","article-title":"A systematic literature review of utility weights in wet age-related macular degeneration.","volume":"16","author":"Pearson","year":"2013","journal-title":"J Med Econ"},{"issue":"7","key":"eoi200114r20","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1016\/j.jcrs.2019.02.006","article-title":"Cost-utility analysis of cataract surgery in the United States for the year 2018.","volume":"45","author":"Brown","year":"2019","journal-title":"J Cataract Refract Surg"},{"key":"eoi200114r21","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.ajo.2020.05.029","article-title":"Patient preference-based cost-utility analysis of VEGF-inhibitor therapy for neovascular age-related macular degeneration in the United States in 2018.","volume":"218","author":"Brown","year":"2020","journal-title":"Am J Ophthalmol"},{"issue":"20","key":"eoi200114r22","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects.","volume":"310","author":"World Medical Association","year":"2013","journal-title":"JAMA"},{"issue":"7","key":"eoi200114r23","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1016\/j.ophtha.2017.12.033","article-title":"Vision-related quality-of-life associated with unilateral and bilateral ocular conditions.","volume":"125","author":"Brown","year":"2018","journal-title":"Ophthalmology"},{"issue":"8","key":"eoi200114r24","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1016\/j.ophtha.2016.03.045","article-title":"Five-year outcomes with anti-vascular endothelial growth factor treatment of neovascular age-related macular degeneration: the Comparison of Age-related Macular Degeneration Treatments Trials.","volume":"123","author":"Maguire","year":"2016","journal-title":"Ophthalmology"},{"issue":"1","key":"eoi200114r25","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.ajo.2006.09.043","article-title":"Progressive visual loss in subfoveal exudation in age-related macular degeneration: a meta-analysis using Lineweaver-Burke plots.","volume":"143","author":"Shah","year":"2007","journal-title":"Am J Ophthalmol"},{"issue":"6","key":"eoi200114r26","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0218462","article-title":"Racial\/ethnic differences in multimorbidity development and chronic disease accumulation for middle-aged adults.","volume":"14","author":"Qui\u00f1ones","year":"2019","journal-title":"PLoS One"},{"issue":"12","key":"eoi200114r27","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1001\/jamaophthalmol.2014.2847","article-title":"Longitudinal relationships among visual acuity, daily functional status, and mortality: the Salisbury Eye Evaluation Study.","volume":"132","author":"Christ","year":"2014","journal-title":"JAMA Ophthalmol"},{"issue":"2","key":"eoi200114r30","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1177\/0272989X9301300202","article-title":"The Beaver Dam Health Outcomes Study: initial catalog of health-state quality factors.","volume":"13","author":"Fryback","year":"1993","journal-title":"Med Decis Making"},{"issue":"5","key":"eoi200114r33","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1016\/j.jaip.2018.10.016","article-title":"The Severe Asthma Network in Italy: findings and perspectives.","volume":"7","author":"Heffler","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"4","key":"eoi200114r34","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1111\/j.1523-1755.2004.00921.x","article-title":"Pain patterns in patients with polycystic kidney disease.","volume":"66","author":"Bajwa","year":"2004","journal-title":"Kidney Int"},{"issue":"7","key":"eoi200114r35","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.medcli.2019.06.021","article-title":"Impact of the new criteria of the ACC\/AHA on the diagnostic prevalence of hypertension.","volume":"154","author":"Baena D\u00edez","year":"2020","journal-title":"Med Clin (Barc)"},{"issue":"1","key":"eoi200114r38","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1080\/13696998.2017.1387118","article-title":"A systematic review of pharmacoeconomic guidelines.","volume":"21","author":"Zhao","year":"2018","journal-title":"J Med Econ"},{"key":"eoi200114r39","article-title":"A cost-benefit analysis of VEGF-inhibitor therapy for neovascular age-related macular degeneration in the United States.","author":"Brown","journal-title":"Am J Ophthalmol"},{"key":"eoi200114r2","first-page":"151","volume-title":"Evidence-Based to Value-Based Medicine","author":"Brown","year":"2005"},{"key":"eoi200114r31","first-page":"167","volume-title":"Cost-Effectiveness in Health and Medicine","author":"Feeny","year":"2017","edition":"2nd ed"},{"key":"eoi200114r37","first-page":"75","volume-title":"Cost-Effectiveness in Health and Medicine","author":"Owens","year":"2017","edition":"2nd ed"},{"key":"eoi200114r12","unstructured":"TANDV\u00c5RDS- OCH L\u00c4KEMEDELF\u00d6RM\u00c5NSVERKET. Health economics. Updated June 16, 2020. Accessed December 30, 2020. https:\/\/www.tlv.se\/in-english\/medicines\/health-economics.html"},{"key":"eoi200114r19","unstructured":"Health Utilities Inc. Multi-attribute health status classification system: Health Utilities Index Mark 3 (HUI3). Updated April 2018. Accessed August 9, 2020. http:\/\/www.healthutilities.com\/hui3.htm"},{"key":"eoi200114r28","unstructured":"Centers for Medicare & Medicaid Services. Physician fee schedule search. Accessed December 29, 2020. https:\/\/www.cms.gov\/apps\/physician-fee-schedule\/search\/search-criteria.aspx"},{"key":"eoi200114r29","unstructured":"National Institute for Health and Care Excellence. Developing NICE guidelines: the manual. Published October 31, 2014. Accessed September 11, 2020. https:\/\/www.nice.org.uk\/process\/pmg20\/resources\/developing-nice-guidelines-the-manual-pdf-72286708700869?"},{"key":"eoi200114r32","unstructured":"Centers for Medicare & Medicaid Services. Health Outcomes Survey (HOS). Modified November 19, 2020. Accessed October 19, 2020. https:\/\/www.cms.gov\/Research-Statistics-Data-and-Systems\/Research\/HOS"},{"key":"eoi200114r36","unstructured":"Centers for Disease Control and Prevention. National Diabetes Statistics Report 2020: estimate of diabetes and its burden in the United States. Accessed December 30, 2020. https:\/\/www.cdc.gov\/diabetes\/pdfs\/data\/statistics\/national-diabetes-statistics-report.pdf"}],"container-title":["JAMA Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaophthalmology\/articlepdf\/2775808\/jamaophthalmology_brown_2021_oi_200114_1618442151.28364.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,22]],"date-time":"2021-04-22T12:37:30Z","timestamp":1619095050000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaophthalmology\/fullarticle\/2775808"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,1]]},"references-count":39,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,4,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaophthalmol.2020.6591","relation":{},"ISSN":["2168-6165"],"issn-type":[{"value":"2168-6165","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4,1]]}}}